Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
1.510
+0.030 (2.03%)
Jan 21, 2025, 4:00 PM EST - Market closed
Theriva Biologics Employees
Theriva Biologics had 22 employees as of December 31, 2023. The number of employees increased by 1 or 4.76% compared to the previous year.
Employees
22
Change (1Y)
1
Growth (1Y)
4.76%
Revenue / Employee
n/a
Profits / Employee
-$1,213,227
Market Cap
4.20M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
TOVX News
- 6 weeks ago - Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 3 months ago - Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - GlobeNewsWire
- 4 months ago - Theriva Biologics Announces Pricing of $2.5 Million Public Offering - GlobeNewsWire
- 4 months ago - Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 4 months ago - Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program - GlobeNewsWire
- 5 months ago - Theriva Biologics Announces Reverse Stock Split - GlobeNewsWire
- 6 months ago - Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma - GlobeNewsWire
- 8 months ago - Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire